Inventor · disambiguated record
Wan Namkung
Also filed as: NAMKUNG WAN
4 granted patents·4 pending applications·2 citations·filing 2010–2023
58Inventor score
Files withUNIV YONSEI IACF3VERKMAN ALAN S2ARBORMED CO LTD1UIF UNIV INDUSTRY FOUNDATION YONSEI UNIV1YONSEI UNIV UNIV INDUSTRY FOUNDATION UIF1
Top patents by PatentIndex Score
8 records- 0172US9296751B1Indolizino[3,2-c]quinoline derivatives, pharmaceutically acceptable salt thereof, preparation method thereof and pharmaceutical composition for treatment of cystic fibrosis containing the same as active ingredientUNIV YONSEI IACF·Filed 2015·Granted Mar 29, 2016·2 cites·15 claims
- 0260US2025340537A1Pharmaceutically active compounds, compositions, and methods for modulating pendrinARBORMED CO LTD·Filed 2023·Application pending·0 cites
- 0357US11957699B2Composition comprising punicalagin for inhibiting PAR2 activityUNIV YONSEI IACF·Filed 2019·Granted Apr 16, 2024·0 cites·3 claims
- 0456US2024287042A1Novel compound having inhibitory activity against pendrin, and pharmaceutical uses thereofUIF UNIV INDUSTRY FOUNDATION YONSEI UNIV·Filed 2022·Application pending·0 cites
- 0554US11274074B2Pharmaceutical composition for ANO1 antagonist with anticancer activityUNIV YONSEI IACF·Filed 2019·Granted Mar 15, 2022·0 cites·3 claims
- 0647US9790218B2Small molecule activators of calcium-activated chloride channels and methods of useVERKMAN ALAN S·Filed 2012·Granted Oct 17, 2017·0 cites·8 claims
- 0747US2022193041A1Novel compound and method for preventing or treating of respiratory diseases comprising the same as an active ingredientYONSEI UNIV UNIV INDUSTRY FOUNDATION UIF·Filed 2020·Application pending·0 cites
- 0830US2012202876A1Methods of treating diseases with proanthocyanidin oligomers such as crofelemerVERKMAN ALAN S·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Wan Namkung files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →